- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2015-06-30 18:47:33
- Reporting Period:
- Filing Date:
- Accepted Time:
- 2015-06-30 18:47:33
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1454789||Catabasis Pharmaceuticals Inc||CATB||Pharmaceutical Preparations (2834)||000000000|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1252522||Nicholas Galakatos||C/o Clarus Ventures, Llc |
101 Main Street Suite 1210
Cambridge MA 02142
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Common Stock||Acquisiton||2015-06-30||1,618,676||$0.00||1,618,676||No||4||C||Indirect||See Footnotes|
|Common Stock||Acquisiton||2015-06-30||757,117||$0.00||2,375,793||No||4||C||Indirect||See Footnotes|
|Common Stock||Acquisiton||2015-06-30||376,695||$12.00||2,752,488||No||4||P||Indirect||See Footnotes|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
Reported Derivative Transactions
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Series A Preferred Stock||Disposition||2015-06-30||20,800,000||$0.00||1,618,676||$0.00|
|Common Stock||Series B Preferred Stock||Disposition||2015-06-30||9,728,971||$0.00||757,117||$0.00|
|Common Stock||Stock Option (right to buy)||Acquisiton||2015-06-30||11,094||$0.00||11,094||$12.21|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
- The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- These shares are owned directly by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus.
- The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Dr. Galakatos, Denis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Galakatos disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
- This option was granted on June 30, 2015 and vests over three years, with one-third of the shares vesting on each anniversary of the grant date until the third anniversary of the grant date.